The paper “The Changing Landscape of Opportunity for Cure of Severe Hemoglobinopathies in Middle-Income Regions” authored by our longstanding partner, Dr. Lawrence Faulkner from the Cure2Children Foundation, sheds light on the evolving landscape of hematopoietic stem cell transplantation (HSCT) and emerging gene therapies for patients with severe hemoglobinopathies, including β-thalassemia and sickle cell disease. It explores how HSCT can be implemented more widely in low- and middle-income countries through targeted collaboration, local expertise, sustainable financing, and investment in local capacity.

The article highlights our Access to Transplantation program and our joint efforts with the Cure2Children Foundation and the Sankalp India Foundation, which have helped make HSCT more accessible to children with hemoglobinopathies in resource-constrained settings.

“At DKMS, we believe access to life-saving treatment should not depend on where a patient is born,” says Dr. Elke Neujahr, Global CEO of DKMS. “Through strategic partnerships and our Access to Transplantation program, we are committed to ensuring that more children and young adults around the world have the chance to receive lifesaving stem cell transplants.”

Our commitment to more equitable access to treatment

As most individuals affected by hemoglobinopathies live in low- and middle-income countries, improving access to transplantation is a key part of our mission. We remain committed to supporting transplant programs and healthcare systems so that more patients in low- and middle-income countries can get a second chance at life.

Read more about our Access to Transplantation activities here.

Full article: https://www.mdpi.com/2039-4365/15/1/3

Journal: Pediatric Reports, Vol. 15, Issue 1 (2025)